The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study providing in-vitro surveillance
data on microbial susceptibility in centers that prescribe meropenem. This paper summarizes data on the activity of meropenem and five
comparator agents against 13,793 clinical isolates from 31 centers in 10 European countries, 1997–2000. Meropenem and imipenem
demonstrated broad-spectrum activity against the tested organisms, including B-lactamase-producing strains that were co-resistant to
quinolones and aminoglycosides. The carbapenems were active against the most frequently isolated pathogens including staphylococci
(98–100% susceptible), Pseudomonas aeruginosa (65–82% susceptible) and Klebsiella pneumoniae (98–100% susceptible). Resistance to
penicillins and cephalosporins was observed, particularly among Enterobacter species in Southern and Eastern Europe. Eastern Europe
showed a high prevalence of AmpC B-lactamase and extended-spectrum B-lactamase-producing strains in Russia (2000); 47% and 28% of
Enterobacteriaceae isolates were AmpC or ESBL-producers, respectively. There was no significant decrease in susceptibility to the
carbapenems throughout the four-year period. Meropenem and imipenem appear to remain reliable options for the treatment of serious
nosocomial infections.

• Quantitative data - Quantitative data were used during the intervention

• Human - All activities regarding organisations and individuals involved in health products and services

• Healthcare delivery